2. Search Result
Search Result
Isoforms Recommended: IDO1
Results for "

Apo-IDO1

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111540
    LY-3381916
    2 Publications Verification

    IDO1-IN-5

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    LY-3381916 (IDO1-IN-5) is a potent, selective and brain penetrated inhibitor of IDO1 activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1 [1].
    LY-3381916
  • HY-111540B
    (S)-LY-3381916
    1 Publications Verification

    (S)-IDO1-IN-5

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    (S)-LY-3381916 ((S)-IDO1-IN-5; Example 1B) is an active S-isomer of LY-3381916. (S)-LY-3381916 binds to IDOL with an IC50 value less than 1.5 µΜ [1]. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1 .
    (S)-LY-3381916
  • HY-177784
    iDeg-3

    		Molecular Glues Indoleamine 2,3-Dioxygenase (IDO) Infection Neurological Disease Cancer
    iDeg-3 is a selective molecular glue degrader that targets IDO1. iDeg-3 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 46 nM). iDeg-3 can be used for the researches of cancer, infection and neurological disease, such as melanoma [1].
    iDeg-3
  • HY-178011
    IDO1-IN-28

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-28 (Compound MQ-1) is a Apo-IDO1 inhibitor with an IC50 of 1.29  μM. IDO1-IN-28 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-28 can be used for cancers research [1].
    IDO1-IN-28
  • HY-178024
    IDO1-IN-29

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-29 (Compound MQ-1n) is a Apo-IDO1 inhibitor with an IC50 of 0.29  μM. IDO1-IN-29 selectively targets apo-IDO1 and disrupts heme binding. IDO1-IN-29 can be used for cancers research [1].
    IDO1-IN-29
  • HY-177785
    iDeg-6

    		Molecular Glues Indoleamine 2,3-Dioxygenase (IDO) Infection Neurological Disease Cancer
    iDeg-6 is a selective molecular glue degrader that targets IDO1 with a DC50 of 6.5 nM. iDeg-6 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 1.6 μM). iDeg-6 can be used for the researches of cancer, infection and neurological disease, such as melanoma [1].
    iDeg-6
  • HY-172453
    XW-032

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    XW-032 is an apo-IDO1 inhibitor, with an IC50 of 21 nM. XW-032 (TGI = 63%) exhibits potent in vivo anti-tumor efficacy in the CT26 syngeneic mouse model and is expected to be applied in the research of the field of cancer [1].
    XW-032
  • HY-178954
    IDO1-IN-32

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-32 (Compound 45) is a potent and orally effective IDO1 inhibitor with an IC50 of 10 pM. IDO1-IN-32 exhibits significant anti-proliferative activity against Hela cells. IDO1-IN-32 can significantly inhibit tumor growth in CT26 and LCC transplanted mouse models by activating anti-tumor immunity. IDO1-IN-32 can be used for research on colon cancer and breast cancer [1].
    IDO1-IN-32
  • HY-111540A
    (Rac)-LY-3381916

    (Rac)-IDO1-IN-5

    		 Indoleamine 2,3-Dioxygenase (IDO) Cancer
    (Rac)-LY-3381916 ((Rac)-IDO1-IN-5; Example 1) is a racemate of LY-3381916 [1]. LY-3381916 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1 .
    (Rac)-LY-3381916
  • HY-181947
    IDO1-IN-33

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IDO1-IN-33 (Compound YC-16) is a IDO1 inhibitor (with an IC50 of 0.18 μM for IDO1 in HeLa cells). IDO1-IN-33 acts as an apo-IDO1 inhibitor by slowly and competitively displacing heme from mature holo-IDO1 and rapidly binding to the heme-binding site of immature apo-IDO1, without altering the expression level of IDO1. IDO1-IN-33 can be used for the research of hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, and cervical cancer [1].
    IDO1-IN-33

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: